Cargando…

Combined Inhibition of TGF-β1-Induced EMT and PD-L1 Silencing Re-Sensitizes Hepatocellular Carcinoma to Sorafenib Treatment

Hepatocellular carcinoma (HCC) is the most common type of primary hepatic malignancy. HCC is one of the leading causes of cancer deaths worldwide. The oral multi-tyrosine kinase inhibitor Sorafenib is the standard first-line therapy in patients with advanced unresectable HCC. Despite the significant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shrestha, Ritu, Prithviraj, Prashanth, Bridle, Kim R., Crawford, Darrell H. G., Jayachandran, Aparna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8123871/ https://www.ncbi.nlm.nih.gov/pubmed/33925488 http://dx.doi.org/10.3390/jcm10091889

Ejemplares similares

CD73 and PD-L1 as Potential Therapeutic Targets in Gallbladder Cancer
por: Cao, Lu, et al.
Publicado: (2022)

Immune checkpoint molecules are regulated by transforming growth factor (TGF)-β1-induced epithelial-to-mesenchymal transition in hepatocellular carcinoma
por: Shrestha, Ritu, et al.
Publicado: (2021)

Monitoring Immune Checkpoint Regulators as Predictive Biomarkers in Hepatocellular Carcinoma
por: Shrestha, Ritu, et al.
Publicado: (2018)

Dual Targeting of Sorafenib-Resistant HCC-Derived Cancer Stem Cells
por: Shrestha, Ritu, et al.
Publicado: (2021)

TNF-α-mediated epithelial-to-mesenchymal transition regulates expression of immune checkpoint molecules in hepatocellular carcinoma
por: Shrestha, Ritu, et al.
Publicado: (2020)

Prognostic Role of Immune Checkpoint Regulators in Cholangiocarcinoma: A Pilot Study
por: Cao, Lu, et al.
Publicado: (2021)

Crosstalk between Immune Checkpoint Modulators, Metabolic Reprogramming and Cellular Plasticity in Triple-Negative Breast Cancer
por: Poddar, Arpita, et al.
Publicado: (2022)

Embryonic Chicken Transplantation is a Promising Model for Studying the Invasive Behavior of Melanoma Cells
por: Jayachandran, Aparna, et al.
Publicado: (2015)

Silencing KIF14 reverses acquired resistance to sorafenib in hepatocellular carcinoma
por: Zhu, Qiankun, et al.
Publicado: (2020)

Galectin-1 induces hepatocellular carcinoma EMT and sorafenib resistance by activating FAK/PI3K/AKT signaling
por: Zhang, P-F, et al.
Publicado: (2016)

Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma
por: Liu, Jianhua, et al.
Publicado: (2017)

Sorafenib-resistant hepatocellular carcinoma stratified by phosphorylated ERK activates PD-1 immune checkpoint
por: Chen, Jiang, et al.
Publicado: (2016)

PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus regorafenib in patients with advanced hepatocellular carcinoma after failure of sorafenib
por: Xu, Yongkang, et al.
Publicado: (2022)

Real-World Effectiveness of Sorafenib versus Lenvatinib Combined with PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma
por: Chiang, Hsueh-Chien, et al.
Publicado: (2023)

Transketolase-like 1 ectopic expression is associated with DNA hypomethylation and induces the Warburg effect in melanoma cells
por: Jayachandran, Aparna, et al.
Publicado: (2016)

Down-Regulation of TGF-β Expression Sensitizes the Resistance of Hepatocellular Carcinoma Cells to Sorafenib
por: Kang, Dongxu, et al.
Publicado: (2017)

Zinc finger protein 703 induces EMT and sorafenib resistance in hepatocellular carcinoma by transactivating CLDN4 expression
por: Wang, Hao, et al.
Publicado: (2020)

Dendritic Cells Pulsed with Exosomes in Combination with PD-1 Antibody Increase the Efficacy of Sorafenib in Hepatocellular Carcinoma Model()()
por: Shi, Shengbin, et al.
Publicado: (2018)

Upregulation of PD-L1 expression promotes epithelial-to-mesenchymal transition in sorafenib-resistant hepatocellular carcinoma cells
por: Xu, Gui-Li, et al.
Publicado: (2020)

Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study
por: Chen, San-Chi, et al.
Publicado: (2022)

Thrombospondin 1 promotes an aggressive phenotype through epithelial-to-mesenchymal transition in human melanoma
por: Jayachandran, Aparna, et al.
Publicado: (2014)

Remodeling Serine Synthesis and Metabolism via Nanoparticles (NPs)‐Mediated CFL1 Silencing to Enhance the Sensitivity of Hepatocellular Carcinoma to Sorafenib
por: Li, Senlin, et al.
Publicado: (2023)

Silencing activating transcription factor 2 promotes the anticancer activity of sorafenib in hepatocellular carcinoma cells
por: Luo, Lifang, et al.
Publicado: (2018)

The Transcription Factor GLI1 Mediates TGFβ1 Driven EMT in Hepatocellular Carcinoma via a SNAI1-Dependent Mechanism
por: Zheng, Xin, et al.
Publicado: (2012)

Pregnancy associated plasma protein-A links pregnancy and melanoma progression by promoting cellular migration and invasion
por: Prithviraj, Prashanth, et al.
Publicado: (2015)

TGF-β in developmental and fibrogenic EMTs
por: Lee, Jun Ho, et al.
Publicado: (2022)

Complete Response to the Sequential Treatment with Regorafenib Followed by PD-1 Inhibitor in a Sorafenib-Refractory Hepatocellular Carcinoma Patient
por: Zhang, Er-lei, et al.
Publicado: (2020)

Efficacy and Safety of TACE Combined with Regorafenib Plus PD-1 Inhibitor in the Treatment of Hepatocellular Carcinoma After Sorafenib Resistance
por: Zou, Xinhua, et al.
Publicado: (2023)

Sorafenib, Lenvatinib, or Lenvatinib Combining PD-1 Inhibitors Plus TACE in Unresectable Hepatocellular Carcinoma: A Retrospective Analysis
por: Zhao, Shu, et al.
Publicado: (2022)

LncRNA MALAT1 Modulates TGF-β1-Induced EMT in Keratinocyte
por: Zhang, Liping, et al.
Publicado: (2021)

Polyphenols Modulating Effects of PD-L1/PD-1 Checkpoint and EMT-Mediated PD-L1 Overexpression in Breast Cancer
por: Messeha, Samia S., et al.
Publicado: (2021)

Piezo1 promoted hepatocellular carcinoma progression and EMT through activating TGF-β signaling by recruiting Rab5c
por: Li, Yi-ming, et al.
Publicado: (2022)

Silencing the expression of copine-III enhances the sensitivity of hepatocellular carcinoma cells to the molecular targeted agent sorafenib
por: Chen, Zhuo, et al.
Publicado: (2018)

CASK Silence Overcomes Sorafenib Resistance of Hepatocellular Carcinoma Through Activating Apoptosis and Autophagic Cell Death
por: Ding, Bisha, et al.
Publicado: (2021)

Indirect Comparisons via Sorafenib for the Comparative Effectiveness of Two PD-1/PD-L1 Inhibitors to Treat Advanced Hepatocellular Carcinoma Patients without Prior Systemic Therapies
por: Jiang, Yawen, et al.
Publicado: (2022)

Observational Study of PD-L1, TGF-β, and Immune Cell Infiltrates in Hepatocellular Carcinoma
por: Ihling, Christian, et al.
Publicado: (2019)

A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
por: Kelley, R.K., et al.
Publicado: (2019)

Aberrant pregnancy-associated plasma protein-A expression in breast cancers prognosticates clinical outcomes
por: Prithviraj, Prashanth, et al.
Publicado: (2020)

Midkine inhibition enhances anti-PD-1 immunotherapy in sorafenib-treated hepatocellular carcinoma via preventing immunosuppressive MDSCs infiltration
por: Ding, Lijuan, et al.
Publicado: (2023)

Murine hepatocellular carcinoma derived stem cells reveal epithelial-to-mesenchymal plasticity
por: Jayachandran, Aparna, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_0i9uddu5lkq8f05tc5pillj9rv